Trial Profile

A randomized phase ll study consistiong S-1+DTX and S-1+CDDP for advanced/metastatic gastric cancer without any mesurable lesions (HERBIS-3).

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
Indications Gastric cancer
Focus Therapeutic Use
Acronyms HERBIS-3

Most Recent Events

20 Feb 2019 Status changed from active, no longer recruiting to completed.
18 Aug 2012 Actual initiation date changed from 1 Aug 2011 to 22 Aug 2011 added as reported by University Hospital Medical Information Network - Japan
22 Nov 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com